BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rinvecalinase alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rinvecalinase alfa\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05065216-903@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rinvecalinase alfa: Phase 2/3 readout est. (NCT05065216)
DESCRIPTION:Rinvecalinase alfa\, phase 2/3\, Acute Ischemic Stroke.\nStudy:
  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rinvecalinase-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05065216
URL:https://assetmemo.bio/drug/rinvecalinase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
